TY  - JOUR
AU  - Sprave, Tanja
AU  - Zöller, Daniela
AU  - Stoian, Raluca
AU  - Rühle, Alexander
AU  - Kalckreuth, Tobias
AU  - Haehl, Erik
AU  - Fahrner, Harald
AU  - Binder, Harald
AU  - Grosu, Anca-Ligia
AU  - Heinemann, Felix
AU  - Nicolay, Nils Henrik
TI  - App-Controlled Treatment Monitoring and Support for Head and Neck Cancer Patients (APCOT): Protocol for a Prospective Randomized Controlled Trial.
JO  - JMIR Research Protocols
VL  - 9
IS  - 12
SN  - 1929-0748
CY  - Toronto
M1  - DKFZ-2020-03007
SP  - e21693
PY  - 2020
AB  - Head and neck cancers (HNCs) are among the most common malignancies, which often require multimodal treatment that includes radiation therapy and chemotherapy. Patients with HNC have a high burden of symptoms due to both the damaging effects of the tumor and the aggressive multimodal treatment. Close symptom monitoring over the course of the disease may help to identify patients in need of medical interventions.This APCOT (App-Controlled Treatment Monitoring and Support for Head and Neck Cancer Patients) trial is designed to assess the feasibility of monitoring HNC patients during the course of (chemo)radiation therapy daily using a mobile app. Additionally, symptom patterns, patient satisfaction, and quality of life will be measured in app-monitored patients in comparison to a patient cohort receiving standard-of-care physician appointments, and health economy aspects of app monitoring will be analyzed.This prospective randomized single-center trial will evaluate the feasibility of integrating electronic patient-reported outcome measures (ePROMs) into the treatment workflow of HNC patients. Patients undergoing definitive or adjuvant (chemo)radiation therapy as part of their HNC treatment at the Department of Radiation Oncology, University Medical Center Freiburg (Freiburg, Germany) will receive weekly physician appointments and additional appointments as requested to monitor and potentially treat symptoms during the course of treatment. Patients in the experimental arm will additionally be monitored daily using a dedicated app regarding their disease- and treatment-related symptoms, quality of life, and need for personal physician appointments. The feasibility of ePROM monitoring will be tested as the primary endpoint and will be defined if ≥80
KW  - HNSCC (Other)
KW  - head and neck cancer (Other)
KW  - mHealth (Other)
KW  - mobile app (Other)
KW  - patient-reported outcome measures (Other)
KW  - quality of life (Other)
KW  - radiotherapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:33295291
DO  - DOI:10.2196/21693
UR  - https://inrepo02.dkfz.de/record/166564
ER  -